LABELS · 4e9814fe-3089-4980-a207-bf0aa95d4c36

Solu-Cortef

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-08-27
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

Full extracted label fields

application numbers

NDA009866

boxed warning exact

brand names

Solu-Cortef

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65eefd58-b166-4d71-ade6-45c8fdf86922

generic names

HYDROCORTISONE SODIUM SUCCINATE

4e9814fe-3089-4980-a207-bf0aa95d4c36

indications and usage exact

INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

indications and usage tables exact

is original packager

true

manufacturer names

Pharmacia & Upjohn Company LLC

matched search terms

cancer
lymphomas
tumor

package ndcs

0009-0825-01
0009-0011-03
0009-0011-04
0009-0013-05
0009-0013-06
0009-0016-12
0009-0005-01

product ndcs

0009-0005
0009-0825
0009-0011
0009-0013
0009-0016

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAMUSCULAR
INTRAVENOUS

rxcuis

105398
238755
1738586
1738589
1738590
1738592
1738594
1738596

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 738
end exclusive: true
exact text: INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 0

current approval status

not_reconciled

duplicate text group

dup-7c16c7359c4e58f2067e

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-789fee318cb1f4b4d30f

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

end: 274
end exclusive: true
exact text: is indicated
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 262

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 538
end exclusive: true
exact text: INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 906
end exclusive: true
exact text: allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where a
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 339

current approval status

not_reconciled

duplicate text group

dup-d4d5f42433ad7459482e

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-567436f13045e6281407

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 706
end exclusive: true
exact text: Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 539

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1290
end exclusive: true
exact text: ickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemo
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 507

current approval status

not_reconciled

duplicate text group

dup-22a30fd59f3120553ca2

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-1e2ea86b11b23a9f05b6

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1090
end exclusive: true
exact text: Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 707

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1440
end exclusive: true
exact text: ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administ
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 891

current approval status

not_reconciled

duplicate text group

dup-c3628cc32d978035552c

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-36145ec5268739adc26d

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1240
end exclusive: true
exact text: Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1091

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · risk or warning

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1769
end exclusive: true
exact text: sociated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemoth
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1041

current approval status

not_reconciled

duplicate text group

dup-af087301d51413089c4e

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-81bea5e02881759594ff

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

context exact
nd Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administrat
kind
age
polarity
not_inferred
span
end
1418
end exclusive
true
exact text
adults
label id
4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start
1412

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1569
end exclusive: true
exact text: Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1241

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1975
end exclusive: true
exact text: ), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sy
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1370

current approval status

not_reconciled

duplicate text group

dup-3375cd18f7ef68a9554d

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-68d1a6062e64584944ac

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1775
end exclusive: true
exact text: Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1570

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2054
end exclusive: true
exact text: laneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive t
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1576

current approval status

not_reconciled

duplicate text group

dup-90876cd84bb4d458f486

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-7130b9a20d607b212e9f

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1854
end exclusive: true
exact text: Neoplastic diseases: For the palliative management of leukemias and lymphomas.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1776

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2151
end exclusive: true
exact text: ingitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idio
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1655

current approval status

not_reconciled

duplicate text group

dup-dd90b018027c8abec3c0

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-853e77b10237029dbaf2

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

context exact
Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
1935
end exclusive
true
exact text
metastatic brain tumor
label id
4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start
1913
context exact
Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
1935
end exclusive
true
exact text
metastatic brain tumor
label id
4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start
1913

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1951
end exclusive: true
exact text: Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1855

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2280
end exclusive: true
exact text: berculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pul
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1752

current approval status

not_reconciled

duplicate text group

dup-2067215fba4c26837c91

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-dd474872d46b0016cb46

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2080
end exclusive: true
exact text: Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1952

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2413
end exclusive: true
exact text: dema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptom
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 1881

current approval status

not_reconciled

duplicate text group

dup-6890d0547bc40f77a19b

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-5a75a07db67ebb55364e

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2213
end exclusive: true
exact text: Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 2081

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2630
end exclusive: true
exact text: r inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spo
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 2014

current approval status

not_reconciled

duplicate text group

dup-1790560a077be9f3951d

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-abb58f1be0d19c0f20ac

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2430
end exclusive: true
exact text: Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 2214

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2887
end exclusive: true
exact text: ses: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 2231

current approval status

not_reconciled

duplicate text group

dup-0da793127f22cbac656d

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-f4e29f068b78c36e07cf

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2781
end exclusive: true
exact text: Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 2431

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA009866

brand names

Solu-Cortef

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2887
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 2582

current approval status

not_reconciled

duplicate text group

dup-b3bae166e33932741670

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE SODIUM SUCCINATE

ind-span-9a18c7c941f116342a0e

label id

4e9814fe-3089-4980-a207-bf0aa95d4c36

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2887
end exclusive: true
exact text: For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 4e9814fe-3089-4980-a207-bf0aa95d4c36
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cf881127898f745961f4f422e9b6dd98f2e1d3bbeef1a2b8e350aeee6632cc7a
start: 2782

source url

https://api.fda.gov/drug/label.json?search=id%3A%224e9814fe-3089-4980-a207-bf0aa95d4c36%22

spl effective date

2026-08-27

spl set id

65eefd58-b166-4d71-ade6-45c8fdf86922

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice